{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:21:19Z","timestamp":1787023279562,"version":"build-2736575974"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,1,19]],"date-time":"2015-01-19T00:00:00Z","timestamp":1421625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000064","name":"National Center for Complementary and Alternative Medicine","doi-asserted-by":"publisher","award":["R24 AT001293"],"award-info":[{"award-number":["R24 AT001293"]}],"id":[{"id":"10.13039\/100000064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Many cancer patients receive supplemental ascorbate (vitamin C) in the belief that it synergizes the anticancer effects of chemotherapy and reduces its toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>A systematic review was performed to evaluate the antitumor effects and toxicity of ascorbate treatment. Medline (1946 to March 2014), EMBASE (1947 to March 2014), and the Cochrane central register (1993 to March 2014) were searched for randomized and observational studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Of 696 identified records, 61 full-text articles were screened and 34 were included. In total, 5 randomized controlled trials (RCTs) (n = 322), 12 phase I\/II trials (n = 287), 6 observational studies (n = 7,599), and 11 case reports (n = 267) were identified. Because of study heterogeneity, no meta-analyses were performed. No RCTs reported any statistically significant improvements in overall or progression-free survival or reduced toxicity with ascorbate relative to control arm. Evidence for ascorbate's antitumor effects was limited to case reports and observational and uncontrolled studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>There is no high-quality evidence to suggest that ascorbate supplementation in cancer patients either enhances the antitumor effects of chemotherapy or reduces its toxicity. Given the high financial and time costs to patients of this treatment, high-quality placebo-controlled trials are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2014-0381","type":"journal-article","created":{"date-parts":[[2015,1,19]],"date-time":"2015-01-19T22:08:51Z","timestamp":1421705331000},"page":"210-223","source":"Crossref","is-referenced-by-count":83,"title":["Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer? A Systematic Review"],"prefix":"10.1093","volume":"20","author":[{"given":"Carmel","family":"Jacobs","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Ng","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Shorr","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,1,19]]},"reference":[{"key":"2021122309225134100_B1","first-page":"166","article-title":"Cancer: A collagen disease, secondary to a nutritional deficiency","volume":"76","author":"McCormick","year":"1959","journal-title":"Arch Pediatr"},{"issue":"suppl","key":"2021122309225134100_B2","doi-asserted-by":"crossref","first-page":"1310S","DOI":"10.1093\/ajcn\/54.6.1310s","article-title":"Epidemiologic evidence regarding vitamin C and cancer","volume":"54","author":"Block","year":"1991","journal-title":"Am J Clin Nutr"},{"key":"2021122309225134100_B3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ajcn\/72.1.139","article-title":"Vitamin C status and mortality in US adults","volume":"72","author":"Loria","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"2021122309225134100_B4","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1023\/A:1018443724293","article-title":"Vitamin supplements and cancer risk: The epidemiologic evidence","volume":"8","author":"Patterson","year":"1997","journal-title":"Cancer Causes Control"},{"key":"2021122309225134100_B5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/biof.5520070115","article-title":"Vitamins E plus C and interacting conutrients required for optimal health: A critical and constructive review of epidemiology and supplementation data regarding cardiovascular disease and cancer","volume":"7","author":"Gey","year":"1998","journal-title":"Biofactors"},{"key":"2021122309225134100_B6","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(04)17138-9","article-title":"Antioxidant supplements for prevention of gastrointestinal cancers: A systematic review and meta-analysis","volume":"364","author":"Bjelakovic","year":"2004","journal-title":"Lancet"},{"key":"2021122309225134100_B7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jama.2008.862","article-title":"Vitamins E and C in the prevention of prostate and total cancer in men: The Physicians\u2019 Health Study II randomized controlled trial","volume":"301","author":"Gaziano","year":"2009","journal-title":"JAMA"},{"key":"2021122309225134100_B8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djn438","article-title":"Vitamins C and E and beta carotene supplementation and cancer risk: A randomized controlled trial","volume":"101","author":"Lin","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2021122309225134100_B9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0009-2797(74)90019-2","article-title":"The orthomolecular treatment of cancer: II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer","volume":"9","author":"Cameron","year":"1974","journal-title":"Chem Biol Interact"},{"key":"2021122309225134100_B10","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1073\/pnas.73.10.3685","article-title":"Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer","volume":"73","author":"Cameron","year":"1976","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309225134100_B11","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1073\/pnas.75.9.4538","article-title":"Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer","volume":"75","author":"Cameron","year":"1978","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309225134100_B12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJM197909273011303","article-title":"Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial","volume":"301","author":"Creagan","year":"1979","journal-title":"N Engl J Med"},{"key":"2021122309225134100_B13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJM198501173120301","article-title":"High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: A randomized double-blind comparison","volume":"312","author":"Moertel","year":"1985","journal-title":"N Engl J Med"},{"key":"2021122309225134100_B14","first-page":"443","article-title":"Ascorbic acid: Chemistry, biology and the treatment of cancer","volume":"1826","author":"Du","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2021122309225134100_B15","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1073\/pnas.93.8.3704","article-title":"Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance","volume":"93","author":"Levine","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309225134100_B16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-140-7-200404060-00010","article-title":"Vitamin C pharmacokinetics: Implications for oral and intravenous use","volume":"140","author":"Padayatty","year":"2004","journal-title":"Ann Intern Med"},{"key":"2021122309225134100_B17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000360381","article-title":"Online survey of patients with breast cancer on complementary and alternative medicine","volume":"9","author":"Huebner","year":"2014","journal-title":"Breast Care (Basel)"},{"key":"2021122309225134100_B18","doi-asserted-by":"crossref","first-page":"e11414","DOI":"10.1371\/journal.pone.0011414","article-title":"Vitamin C: Intravenous use by complementary and alternative medicine practitioners and adverse effects","volume":"5","author":"Padayatty","year":"2010","journal-title":"PLoS One"},{"key":"2021122309225134100_B19","volume-title":"An analysis of markets, trends, competition and strategy in the U.S. dietary supplement industry: NBJ's Supplement Business Report","author":"Nutrition Business Journal"},{"key":"2021122309225134100_B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"2021122309225134100_B21","volume-title":"Wells GASB, O'Connell D, Peterson J et al. The newcastle-ottawa scale (nos) for assessing the quality of nonrandomised studies in meta-analyses"},{"key":"2021122309225134100_B22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000226988","article-title":"Reticulum cell sarcoma: Two complete \u2018spontaneous\u2019 regressions, in response to high-dose ascorbic acid therapy: A report on subsequent progress","volume":"48","author":"Campbell","year":"1991","journal-title":"Oncology"},{"key":"2021122309225134100_B23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0009-2797(75)90007-1","article-title":"The orthomolecular treatment of cancer: III. Reticulum cell sarcoma: Double complete regression induced by high-dose ascorbic acid therapy","volume":"11","author":"Cameron","year":"1975","journal-title":"Chem Biol Interact"},{"key":"2021122309225134100_B24","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2021122309225134100_B25","first-page":"333","article-title":"Emerging role of ascorbic acid in the management of advanced breast carcinoma as a chemosensitizer","volume":"22","author":"Goel","year":"1999","journal-title":"Asian J Surg"},{"key":"2021122309225134100_B26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/bjc.2013.269","article-title":"Vitamin C intake and breast cancer mortality in a cohort of Swedish women","volume":"109","author":"Harris","year":"2013","journal-title":"Br J Cancer"},{"key":"2021122309225134100_B27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1600-0609.2009.01244.x","article-title":"Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: An effective and well-tolerated frontline regimen","volume":"82","author":"Berenson","year":"2009","journal-title":"Eur J Haematol"},{"key":"2021122309225134100_B28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF02552617","article-title":"Treatment of desmoid tumors in Gardner's syndrome. Report of a case","volume":"31","author":"Itoh","year":"1988","journal-title":"Dis Colon Rectum"},{"key":"2021122309225134100_B29","doi-asserted-by":"crossref","first-page":"222ra218","DOI":"10.1126\/scitranslmed.3007154","article-title":"High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy","volume":"6","author":"Ma","year":"2014","journal-title":"Sci Transl Med"},{"key":"2021122309225134100_B30","first-page":"983","article-title":"Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-\/radiotherapy and aftercare: Results of a retrospective, multicentre, epidemiological cohort study in Germany","volume":"25","author":"Vollbracht","year":"2011","journal-title":"In Vivo"},{"key":"2021122309225134100_B31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00280-013-2179-9","article-title":"Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer","volume":"72","author":"Stephenson","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309225134100_B32","first-page":"3658","article-title":"Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed\/refractory multiple myeloma","volume":"8","author":"Bahlis","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2021122309225134100_B33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1385\/MO:23:2:263","article-title":"Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: A phase 2 trial","volume":"23","author":"Abou-Jawde","year":"2006","journal-title":"Med Oncol"},{"key":"2021122309225134100_B34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hon.870","article-title":"Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: A Wisconsin Oncology Network study","volume":"27","author":"Chang","year":"2009","journal-title":"Hematol Oncol"},{"key":"2021122309225134100_B35","first-page":"1722","article-title":"Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"91","author":"Wu","year":"2006","journal-title":"Haematologica"},{"key":"2021122309225134100_B36","doi-asserted-by":"crossref","first-page":"e29794","DOI":"10.1371\/journal.pone.0029794","article-title":"Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer","volume":"7","author":"Monti","year":"2012","journal-title":"PLoS One"},{"key":"2021122309225134100_B37","first-page":"269","article-title":"A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients","volume":"24","author":"Riordan","year":"2005","journal-title":"P R Health Sci J"},{"key":"2021122309225134100_B38","doi-asserted-by":"crossref","first-page":"B71","DOI":"10.1053\/j.ajkd.2011.02.223","article-title":"Acute oxalate nephropathy from intravenous vitamin C therapy","volume":"57","author":"Nangia","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2021122309225134100_B39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1479-5876-10-189","article-title":"Effect of high-dose intravenous vitamin C on inflammation in cancer patients","volume":"10","author":"Mikirova","year":"2012","journal-title":"J Transl Med"},{"key":"2021122309225134100_B40","first-page":"115","article-title":"Intravenous vitamin C as a chemotherapy agent: A report on clinical cases","volume":"23","author":"Riordan","year":"2004","journal-title":"P R Health Sci J"},{"key":"2021122309225134100_B41","first-page":"117","article-title":"Sixteen year history with high dose intravenous vitamin C treatment for various types of cancer and other diseases","volume":"17","author":"Jackson","year":"2002","journal-title":"J Orthomol Med"},{"key":"2021122309225134100_B42","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1503\/cmaj.050346","article-title":"Intravenously administered vitamin C as cancer therapy: Three cases","volume":"174","author":"Padayatty","year":"2006","journal-title":"CMAJ"},{"key":"2021122309225134100_B43","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-013-2070-8","article-title":"Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): Results from a phase I clinical trial","volume":"71","author":"Welsh","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309225134100_B44","first-page":"66","article-title":"Relief from cancer chemotherapy side effects with pharmacologic vitamin C","volume":"127","author":"Carr","year":"2014","journal-title":"N Z Med J"},{"key":"2021122309225134100_B45","first-page":"179","article-title":"Ukrain (NSC-631570) in the treatment of pancreas cancer","volume":"26","author":"Zemskov","year":"2000","journal-title":"Drugs Exp Clin Res"},{"key":"2021122309225134100_B46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0306-9877(91)90127-K","article-title":"Innovation vs. quality control: An \u2018unpublishable\u2019 clinical trial of supplemental ascorbate in incurable cancer","volume":"36","author":"Cameron","year":"1991","journal-title":"Med Hypotheses"},{"key":"2021122309225134100_B47","first-page":"103","article-title":"Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate","volume":"23","author":"Murata","year":"1982","journal-title":"Int J Vitam Nutr Res Suppl"},{"key":"2021122309225134100_B48","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/annonc\/mdn377","article-title":"Phase I clinical trial of I.V. ascorbic acid in advanced malignancy","volume":"19","author":"Hoffer","year":"2008","journal-title":"Annals Oncol"},{"key":"2021122309225134100_B49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pmu.2012.05.008","article-title":"High-dose intravenous vitamin C improves quality of life in cancer patients","volume":"1","author":"Takahashi","year":"2012","journal-title":"Personalized Medicine Universe"},{"key":"2021122309225134100_B50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3346\/jkms.2007.22.1.7","article-title":"Changes of terminal cancer patients\u2019 health-related quality of life after high dose vitamin C administration","volume":"22","author":"Yeom","year":"2007","journal-title":"J Korean Med Sci"},{"key":"2021122309225134100_B51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/003693307902400210","article-title":"Acute reactions to mega ascorbic acid therapy in malignant disease","volume":"24","author":"Campbell","year":"1979","journal-title":"Scott Med J"},{"key":"2021122309225134100_B52","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/07315724.2003.10719284","article-title":"The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer","volume":"22","author":"Drisko","year":"2003","journal-title":"J Am Coll Nutr"},{"key":"2021122309225134100_B53","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"key":"2021122309225134100_B54","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122309225134100_B55","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJM199811053391901","article-title":"Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide","volume":"339","author":"Soignet","year":"1998","journal-title":"N Engl J Med"},{"key":"2021122309225134100_B56","volume-title":"National Cancer Institute. Ctc v2.0. 1999"},{"key":"2021122309225134100_B57","volume-title":"CONSORT. The CONSORT statement. 2010"},{"key":"2021122309225134100_B58","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0959-8049(97)00395-X","article-title":"A cross-validation of the European Organization for Research and Treatment of Cancer qlq-c30 (EORTC qlq-c30) for Japanese with lung cancer","volume":"34","author":"Kobayashi","year":"1998","journal-title":"Eur J Cancer"},{"issue":"suppl 2","key":"2021122309225134100_B59","doi-asserted-by":"crossref","first-page":"S268","DOI":"10.1111\/j.1440-1746.2008.05414.x","article-title":"Evaluation of EORTC QLQ-C30 questionnaire in patients undergoing in-hospital chemotherapy for gastrointestinal cancer in Japan","volume":"23","author":"Kato","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"2021122309225134100_B60","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"2021122309225134100_B61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ajco.12173","article-title":"Review of high-dose intravenous vitamin C as an anticancer agent","volume":"10","author":"Wilson","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"key":"2021122309225134100_B62","doi-asserted-by":"crossref","DOI":"10.1177\/1534735414534463","article-title":"Intravenous vitamin C and cancer: A systematic review","volume-title":"Poster presented at: Applied Research in Cancer Control","author":"Fritz","year":"2014"},{"key":"2021122309225134100_B63","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1023\/A:1012186203165","article-title":"Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion","volume":"14","author":"Graumlich","year":"1997","journal-title":"Pharm Res"},{"key":"2021122309225134100_B64","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/284629a0","article-title":"Vitamin C preferential toxicity for malignant melanoma cells","volume":"284","author":"Bram","year":"1980","journal-title":"Nature"},{"key":"2021122309225134100_B65","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1054\/bjoc.2001.1814","article-title":"Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours","volume":"84","author":"Casciari","year":"2001","journal-title":"Br J Cancer"},{"key":"2021122309225134100_B66","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/archinte.1985.00360050220044","article-title":"Acute oxalate nephropathy after massive ascorbic acid administration","volume":"145","author":"Lawton","year":"1985","journal-title":"Arch Intern Med"},{"key":"2021122309225134100_B67","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-82-6-810_1","article-title":"Letter: Ascorbic acid-induced hemolysis in G-6-PD deficiency","volume":"82","author":"Campbell","year":"1975","journal-title":"Ann Intern Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2014-0381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0381","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/2\/210\/41869070\/oncolo_20_2_210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/2\/210\/41869070\/oncolo_20_2_210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T21:20:04Z","timestamp":1640294404000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/2\/210\/6399015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,19]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,1,19]]},"published-print":{"date-parts":[[2015,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0381","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,2,1]]},"published":{"date-parts":[[2015,1,19]]}}}